secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001104659-21-134464
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q3 revenue $56.7M (+407% YoY); net loss $0.18/share; 582 clinical trials supported
--------------------------------------------------------------------------------

- Total revenue $56.7M for Q3 2021, up 407% YoY; organic growth 38%.
- Net loss attributable to common stockholders $8.5M ($0.18 per share), vs $11.4M ($0.29) in Q3 2020.
- Adjusted EBITDA $5.6M in Q3 2021, vs -$0.7M in Q3 2020; gross margin 41.5% vs 54.2%.
- Supported 582 clinical trials (up from 561 in Q2 2021) and eight commercial therapies in regenerative medicine.
- Cash and short-term investments $349.5M as of Sep 30, 2021, up from $93.3M on Dec 31, 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465921134464/0001104659-21-134464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465921134464/tm2126235d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-134464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer